Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden

被引:42
|
作者
Hultcrantz, M. [1 ,2 ]
Landtblom, A. Ravn [3 ,4 ]
Andreasson, B. [5 ]
Samuelsson, J. [6 ]
Dickman, P. W. [7 ]
Kristinsson, S. Y. [8 ,9 ]
Bjorkholm, M. [1 ]
Andersson, T. M-L [7 ]
机构
[1] Karolinska Inst, Dept Med, Stockholm, Sweden
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
[3] Stockholm South Hosp, Dept Med, Stockholm, Sweden
[4] Karolinska Inst, Stockholm, Sweden
[5] NU Hosp Grp, Hematol Sect, Uddevalla, Sweden
[6] Univ Hosp Linkoping, Dept Hematol, Linkoping, Sweden
[7] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[8] Univ Iceland, Fac Med, Reykjavik, Iceland
[9] Landspitali Natl Univ Hosp, Dept Hematol, Reykjavik, Iceland
关键词
myeloproliferative neoplasms; polycythemia vera; essential thrombocythemia; primary myelofibrosis; incidence; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; HEMATOLOGIC MALIGNANCIES; MYELOID METAPLASIA; OLMSTED COUNTY; UNITED-STATES; EPIDEMIOLOGY; SURVIVAL; MUTATION;
D O I
10.1111/joim.13019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The reported incidence of Philadelphia-negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in incidence and/or variations in the quality and coverage of the cancer registers. Objective We therefore assessed MPN incidence in Sweden during recent years using prospectively collected information captured in Swedish health registers. Methods Patients with MPNs were identified through the Swedish Cancer Register and Swedish Blood Cancer Register between 2000 and 2014. Information on the Swedish population was obtained from the Human Mortality Database. Crude and age-standardized incidence rates of MPNs with 95% confidence intervals (CIs) were calculated. Results A total of 6281 MPN cases were reported to the Swedish Cancer Register and Swedish Blood Cancer Register during 2000-2014. The age-standardized, to the Swedish population in 2000, incidence for all MPNs was 4.45 (95% confidence interval [CI] 4.34-4.56)/100 000 person-years. The age-standardized incidence for polycythemia vera was 1.48 (1.42-1.54), for essential thrombocythemia 1.60 (1.53-1.66) and for primary myelofibrosis 0.52 (0.48-0.56)/100 000 person-years, respectively. The incidence rate of MPNs was substantially higher in the older compared to the younger age groups. The incidence increased during the study period, likely to do better reporting and increasing age of the general population. Conclusion The reported MPN incidences in our study, which were in the higher interval of previously published studies, are likely more accurate compared to previous reports due to the population-based setting and high level of coverage in the Swedish Cancer and Blood Cancer Registers.
引用
收藏
页码:448 / 454
页数:7
相关论文
共 50 条
  • [41] Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden
    Ji, Jianguang
    Sundquist, Kristina
    Sundquist, Jan
    LANCET ONCOLOGY, 2012, 13 (06): : 642 - 648
  • [42] Trends in Incidence and Mortality of Waldenstrom Macroglobulinemia: A Population-Based Study
    Yin, Xuejiao
    Chen, Lei
    Fan, Fengjuan
    Yan, Han
    Zhang, Yuyang
    Huang, Zhenli
    Sun, Chunyan
    Hu, Yu
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [43] Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study
    Frederiksen, Henrik
    Farkas, Dora Kormendine
    Christiansen, Christian Fynbo
    Larsen, Thomas Stauffer
    Hasselbalch, Hans Carl
    Stentoft, Jesper
    Sorensen, Henrik Toft
    LANCET HAEMATOLOGY, 2015, 2 (07): : E289 - E296
  • [44] Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study
    Kristensen, Daniel Tuyet
    Ovlisen, Andreas Kiesbye
    Jakobsen, Lasse Hjort Kyneb
    Severinsen, Marianne Tang
    Hannig, Louise Hur
    Starklint, Jorn
    Hilsoe, Morten Hagemann
    Vallentin, Anders Pommer
    Brabrand, Mette
    Hasselbalch, Hans Carl
    El-Galaly, Tarec Christoffer
    Roug, Anne Stidsholt
    BLOOD ADVANCES, 2024, 8 (16) : 4478 - 4485
  • [45] Patterns of Care and Outcomes in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Multicenter Population-Based Study
    Szuber, Natasha
    Jolin, Judith
    Harnois, Michael
    BLOOD, 2021, 138
  • [46] Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients
    Landtblom, Anna Ravn
    Andersson, Therese M-L
    Dickman, Paul W.
    Smedby, Karin E.
    Eloranta, Sandra
    Batyrbekova, Nurgul
    Samuelsson, Jan
    Bjorkholm, Magnus
    Hultcrantz, Malin
    LEUKEMIA, 2021, 35 (02) : 476 - 484
  • [47] Factors Associated with Health Care Resource Utilization in Myeloproliferative Neoplasms: A Population-Based Cost Study
    Bankar, Aniket
    Zhao, Haoyu
    Iqbal, Javaid
    Coxford, Ruth
    Cheung, Matthew
    Mozessohn, Lee
    Earle, Craig C.
    Gupta, Vikas
    BLOOD, 2019, 134
  • [48] Population-based incidence and survival of AL amyloidosis in Sweden
    Rosengren, Sara
    Carlson, Kristina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S52 - S53
  • [49] The Incidence and Age Distribution of Leukemias in Armenia: A Population-Based Study
    Arakelyan, Jemma
    Avetisyan, Liana
    Andreasyan, Diana
    Torosyan, Arevik
    Sargsyan, Lilit
    Hakobyan, Lusine
    Iskanyan, Samvel
    Bardakchyan, Samvel
    Mkhitaryan, Sergey
    Papyan, Ruzanna
    Tananyan, Armen
    Tamamyan, Gevorg
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S267 - S268
  • [50] Incidence trends and relative survival of colorectal neuroendocrine neoplasms: A population-based study using German cancer registry data
    Moeller, Lennart
    Szentkiralyi, Andras
    Eisfeld, Christine
    Wellmann, Ina
    Rees, Franziska
    Claassen, Kevin
    Oesterling, Florian
    Kajueter, Hiltraud
    Stang, Andreas
    INTERNATIONAL JOURNAL OF CANCER, 2025,